BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17484832)

  • 1. [Persistent polyarticular synovitis after treatment with alendronate].
    Frederiksen L; Junker P; Brixen KT
    Ugeskr Laeger; 2007 Apr; 169(17):1583-4. PubMed ID: 17484832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate-induced synovitis.
    Gwynne Jones DP; Savage RL; Highton J
    J Rheumatol; 2008 Mar; 35(3):537-8. PubMed ID: 18203307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible alendronate-induced polyarticular synovitis.
    Gökkus K; Yazicioglu G; Sagtas E; Uyan A; Aydin AT
    J Postgrad Med; 2016; 62(2):126-8. PubMed ID: 26767974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy.
    Richards JC; Wiffen SJ
    Cornea; 2006 Oct; 25(9):1100-1. PubMed ID: 17133063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse cutaneous drug reaction to alendronate.
    Brinkmeier T; Kügler K; Lepoittevin JP; Frosch PJ
    Contact Dermatitis; 2007 Aug; 57(2):123-5. PubMed ID: 17627657
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate- and risedronate-induced acute polyarthritis.
    Uğurlar M
    Osteoporos Int; 2016 Nov; 27(11):3383-3385. PubMed ID: 27376840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 12. Alendronate-induced asthma.
    Isik A; Uras I; Uyar ME; Karakurt F; Kaftan O
    Ann Pharmacother; 2009 Mar; 43(3):547-8. PubMed ID: 19261958
    [No Abstract]   [Full Text] [Related]  

  • 13. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
    Terashima T; Hiramatsu K; Shimatani A; Matsuda M; Ogino H; Satomura Y; Noda Y
    Endoscopy; 2006; 38 Suppl 2():E37. PubMed ID: 17366400
    [No Abstract]   [Full Text] [Related]  

  • 15. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
    Stepan JJ; Burr DB; Pavo I; Sipos A; Michalska D; Li J; Fahrleitner-Pammer A; Petto H; Westmore M; Michalsky D; Sato M; Dobnig H
    Bone; 2007 Sep; 41(3):378-85. PubMed ID: 17597017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 17. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD
    MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of alendronate and risk of incident atrial fibrillation in women.
    Heckbert SR; Li G; Cummings SR; Smith NL; Psaty BM
    Arch Intern Med; 2008 Apr; 168(8):826-31. PubMed ID: 18443257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's the story with Fosamax? Recent reports have women wondering if they should stop taking this widely prescribed osteoporosis drug.
    Harv Womens Health Watch; 2008 Nov; 16(3):1-2. PubMed ID: 19043857
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.